EX1 Share Price Performance
Recent EX1 News & Updates
No updates
Exopharm Limited Key Details
Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.016
- Gross Margin
- 0.83%
- Net Profit Margin
- -210.14%
- Debt/Equity Ratio
- 37.2%
Exopharm Limited Competitors
About EX1
- Founded
- 2013
- Employees
- 50
- CEO
- WebsiteView website
Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company’s technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine. The company was incorporated in 2013 and is based in Camberwell, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.5%
- 1 Year: 8.6%
- Year to Date: 5.1%
The market has been flat in the last week, however the Materials sector is down 4.2%. As for the longer term, the market has risen 8.6% in the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading